ClinicaliQ Trial Snapshot
- Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation — Recruiting • Phase III • NCT06830798.
- Ravulizumab drug reduced need for dialysis after kidney transplant compared to placebo in high-risk patients.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after undergoing transplant of deceased donor kidney. Conditions: Delayed Graft Function, DGF, Kidney Transplant Interventions: Ravulizumab, Placebo Lead Sponsor: Alexion Pharmaceuticals, Inc. Planned Enrollment: 450 participants